Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.59 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4742620 | 0.93 | THRB (0.64) | MAPTMEN1KMT2AMAPK10ALDH1A1 | |
| SCHEMBL22395760 | 0.88 | ALDH1A1 (0.52) | ALDH1A1 | |
| SCHEMBL2943134 | 0.84 | PDGFRB (0.63) | MAPTMEN1KMT2AMAPK10ALDH1A1 | |
| SCHEMBL4742591 | 0.84 | THRB (0.72) | MAPTMEN1KMT2AMAPK10ALDH1A1 | |
| SCHEMBL25656123 | 0.83 | MEN1 (0.55) | MAPTMEN1KMT2AMAPK10ALDH1A1 | |
| SCHEMBL4741642 | 0.81 | MAPT (0.64) | MAPTMEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL22395646 | 0.81 | ALDH1A1 (0.73) | ALDH1A1 | |
| SCHEMBL30082217 | 0.81 | ALDH1A1 (0.73) | ALDH1A1 | |
| SCHEMBL23726472 | 0.81 | PDGFRB (0.59) | MAPTMEN1KMT2AMAPK10ALDH1A1 | |
| SCHEMBL30080115 | 0.81 | PDGFRB (0.59) | MAPTMEN1KMT2AMAPK10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4155300-B1 | SUBSTITUTED QUINOLINE ANALOGS AS ALDEHYDE DEHYDROGENASE 1A1 (ALDH1A1) INHIBITORS | US HEALTH (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-3704102-B1 | SUBSTITUTED QUINOLINE ANALOGS AS ALDEHYDE DEHYDROGENASE 1A1 (ALDH1A1) INHIBITORS | US HEALTH (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3704102-B1 | SUBSTITUTED QUINOLINE ANALOGS AS ALDEHYDE DEHYDROGENASE 1A1 (ALDH1A1) INHIBITORS | US HEALTH (US) | 2024-02-28 | — | — | EP | disclosed |
| US-11795177-B2 | Substituted quinoline analogs as aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795177-B2 | Substituted quinoline analogs as aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-10-24 | — | — | US | disclosed |
| US-11795177-B2 | Substituted quinoline analogs as aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-10-24 | — | — | US | disclosed |
| EP-4155300-A1 | SUBSTITUTED QUINOLINE ANALOGS AS ALDEHYDE DEHYDROGENASE 1A1 (ALDH1A1) INHIBITORS | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2023-03-29 | — | — | EP | disclosed |
| EP-4155300-A1 | SUBSTITUTED QUINOLINE ANALOGS AS ALDEHYDE DEHYDROGENASE 1A1 (ALDH1A1) INHIBITORS | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2023-03-29 | — | — | EP | disclosed |
| US-20230079399-A1 | SUBSTITUTED QUINOLINE ANALOGS AS ALDEHYDE DEHYDROGENASE 1A1 (ALDH1A1) INHIBITORS | THE US SECRETARY DEPARTMENT OF H (US) | 2023-03-16 | — | — | US | disclosed |
| US-11505559-B2 | Substituted quinoline analogs as aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH (US) | 2022-11-22 | — | — | US | disclosed |
| US-20210179630-A1 | SUBSTITUTED QUINOLINE ANALOGS AS ALDEHYDE DEHYDROGENASE 1A1 (ALDH1A1) INHIBITORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES | 2021-06-17 | — | — | US | disclosed |
| US-20210179630-A1 | SUBSTITUTED QUINOLINE ANALOGS AS ALDEHYDE DEHYDROGENASE 1A1 (ALDH1A1) INHIBITORS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES | 2021-06-17 | — | — | US | disclosed |
| EP-3704102-A1 | SUBSTITUTED QUINOLINE ANALOGS AS ALDEHYDE DEHYDROGENASE 1A1 (ALDH1A1) INHIBITORS | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2020-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179630-A1 | SUBSTITUTED QUINOLINE ANALOGS AS ALDEHYDE DEHYDROGENASE 1A1 (ALDH1A1) INHIBITORS | ALDH1A1, ALDH1A2, ALDH2 | MAPT 3698/4885MEN1 1555/4885KMT2A 2496/4885 |
| US-11795177-B2 | Substituted quinoline analogs as aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors | ALDH1A1, ALDH1A2, ALDH1B1 | MAPT 3750/4885MEN1 1523/4885KMT2A 2845/4885 |
| US-20230079399-A1 | SUBSTITUTED QUINOLINE ANALOGS AS ALDEHYDE DEHYDROGENASE 1A1 (ALDH1A1) INHIBITORS | ALDH1A1, ALDH1A2, ALDH2 | MAPT 4346/4885MEN1 1755/4885KMT2A 2211/4885 |
| US-11505559-B2 | Substituted quinoline analogs as aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors | ALDH1A1, ALDH1A2, ALDH1B1 | MAPT 3750/4885MEN1 1523/4885KMT2A 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.